Howard Lindzon - Xconomy

Howard Lindzon—

Howard Lindzon
Hedge fund manager and investor. Co-founder, chairman and CEO of StockTwits.
Investment focus:Financial Web, Mobile.
Recent Investments: SPARK Finance, Robinhood, DeskHub
Investment Philosophy:

Underwriters and Partners

Xconomy Insight

From Our Editors · Podcast
Xcelerating Life Sciences Boston: The Highlights Podcast
Learn what's fueling Boston's biotech and digital health investment and partnership opportunities

Sponsored · Webinar
Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges
In vitro assays that tackle the challenges of in vitro hepatotoxicity assessment
Eurofins Discovery

Sponsored · Webinar
July 21 – The Need for Manufacturing Execution Systems (MES) in Cell and Gene Therapy
A discussion on business drivers, technical considerations, special requirements of cell and gene product manufacturing & digitization strategy
Global OT/IT Quality Services

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy Boston

Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients

BioNTech's mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity

Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data

CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy

Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

Roche Gets FDA OK for Injectable Version of Breast Cancer Drug

Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug

Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA

New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech

FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues”

Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage

Akili Interactive’s Video Game for ADHD Gets the FDA All Clear

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

The 2020 National Xconomy Awards

Xcelerating Life Sciences Seattle

Xcelerating Life Sciences New York

Underwriters and Partners

Xcelerating Life Sciences Boston: The Highlights Podcast

Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges

July 21 – The Need for Manufacturing Execution Systems (MES) in Cell and Gene Therapy

Xconomy on Demand

We offer a number of ways to subscribe for free!